Endeavor
57 article(s) found
![immunotherapy.jpg](https://images2.cmp.optimizely.com/assets/immunotherapy.jpg/9f20a12c242b11efbd407a297940f98e)
What Is Immunotherapy?
![](/contentassets/27a4f65299784345b20535dc5f74420f/mdrum_cancer_under_attack-4-1400.jpg)
FDA Set to Approve Earlier Use of CAR T for Multiple Myeloma
![](/contentassets/c4c13d133ba749d19d9d854db0bb1c0d/tandem-hero1.jpg)
Is Outpatient CAR T Therapy Safe for Multiple Myeloma Patients?
![](/contentassets/ba11aeba5ef94e808a6619d8ab0d6792/cart.jpg)
CAR T Effective as First-Line Therapy for High-Risk Lymphoma Patients
![](/contentassets/cffeea2c7b92454090d153c09ccea37d/ash-multipe-myeloma-1400.jpg)
Identifying Inflammatory Markers Related to Toxicities Early Can Improve Multiple Myeloma Treatment
![](/contentassets/31654679ce0543c28f89ff10eafbabfc/lymphoma-cell-1400.jpg)
FDA Investigating ‘Serious Risk’ of Malignancy After CAR T Therapy
![](/contentassets/162e3b2fcc8b4fda9eb415511cfb30dd/larry-parker-1400.jpg)
Patient Marks Moffitt’s 1,000th CAR T Treatment
![](/contentassets/f3586dab6b8147cbb2b37dc964a23cfe/ascohero-mm.jpg)
Cell Therapy Superior to Standard of Care for Multiple Myeloma
![](/contentassets/4be191df41bc4e8bacd7ac4ab72e09b5/mcc-exterior.jpg)
Top 5 Moffitt Research Stories of 2022